Uppsala, Sweden – April 30, 2025 – Inossia AB, a pioneering company in the field of biomaterials for bone health, is pleased to announce the successful completion of its rights issue, which was oversubscribed by more than 100%. Initially targeting 5 million SEK, the rights issue closed at 10.3 million SEK, reflecting strong investor confidence and support.
The strong interest in the rights issue demonstrates the continued confidence of Inossia’s shareholders in the company’s mission to develop soft cements for osteoporotic bone and other innovative solutions for spine augmentation. The proceeds from this capital raise will be used to accelerate ongoing research and development initiatives and support strategic partnerships. Additionally, the funds will be utilized to finalize the clinical report from Inossia’s pivotal clinical study, which will serve as the foundation for regulatory applications in both the US and EU.
“We are thrilled with the overwhelming response to our rights issue the high level of investor interest reflects the confidence in our technology and future growth potential. This funding will enable us to advance our cutting-edge solutions and expand our impact in the field of interventional spine” said Malin Nilsson, CEO of Inossia AB.”
Inossia AB specializes in developing next-generation bone biomaterials, including its proprietary soft bone cement technology, which enhances fracture treatment while preserving patient mobility and comfort. The company continues to make significant strides in clinical applications towards regulatory approvals and commercialization.
For more information, please contact:
Malin Nilsson
CEO
Inossia AB
malin.nilsson@inossia.com
+46 702 688674
About Inossia AB
Inossia AB is a Swedish medical technology company dedicated to improving bone health and spine treatments through innovative biomaterials. Headquartered in Stockholm, the company is committed to advancing fracture care with its novel, patient-friendly solutions. For more information, visit www.inossia.com.
